US 10,376,494 B2
Carboxamide derivative and its diastereomers in stable crystalline form
Olli Törmäkangas, Turku (FI); and Terhi Heikkinen, Lieto (FI)
Assigned to Orion Corporation, Espoo (FI)
Filed by Orion Corporation, Espoo (FI)
Filed on Jun. 4, 2018, as Appl. No. 15/997,040.
Application 15/997,040 is a continuation of application No. 15/547,193, granted, now 10,010,530, previously published as PCT/FI2016/050054, filed on Jan. 28, 2016.
Claims priority of application No. 20150033 (FI), filed on Jan. 30, 2015.
Prior Publication US 2018/0280355 A1, Oct. 4, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4155 (2006.01); A61K 31/277 (2006.01); A61K 31/166 (2006.01); A61K 31/03 (2006.01); C07D 231/14 (2006.01)
CPC A61K 31/4155 (2013.01) [A61K 31/03 (2013.01); A61K 31/166 (2013.01); A61K 31/277 (2013.01); C07D 231/14 (2013.01)] 11 Claims
 
1. Crystalline form I′ of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)-1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia) having an X-ray powder diffraction pattern comprising characteristic peaks at about 9.3, 15.7, 17.0, 24.1, and 25.1 degrees 2-theta, wherein the crystalline form I′ is substantially free of any other crystalline form of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)-1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia).